Valion Bio (VBIO)
NASDAQ:VBIO
Want to see VBIO full AI Analyst Report?
Total Valuation
Valion Bio has a market cap or net worth of $3.01M. The enterprise value is $20.82M.
Market Cap$3.01M
Enterprise Value$20.82M
Share Statistics
Valion Bio has 2,877,926 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,877,926
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valion Bio’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -40.29%.
Return on Equity (ROE)-0.64
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-40.29%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee0.00
Profits Per Employee-293.62K
Employee Count3
Asset Turnover0.08
Inventory Turnover3.02
Valuation Ratios
The current PE Ratio of Valion Bio is ―. Valion Bio’s PEG ratio is -0.73.
PE Ratio―
PS Ratio197.61
PB Ratio17.36
Price to Fair Value17.36
Price to FCF-41.06
Price to Operating Cash Flow168.88
PEG Ratio-0.73
Income Statement
In the last 12 months, Valion Bio had revenue of 0.00 and earned -880.85K in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit0.00
Operating Income-2.34M
Pretax Income-880.85K
Net Income-880.85K
EBITDA-880.85K
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was 964.82K and capital expenditures 0.00, giving a free cash flow of 964.82K billion.
Operating Cash Flow964.82K
Free Cash Flow964.82K
Free Cash Flow per Share0.34
Dividends & Yields
Valion Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change-75.70%
50-Day Moving Average0.91
200-Day Moving Average2.19
Relative Strength Index (RSI)67.56
Average Volume (3m)99.84K
Important Dates
Valion Bio upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Valion Bio as a current ratio of 11.72, with Debt / Equity ratio of 6.52%
Current Ratio11.72
Quick Ratio11.37
Debt to Market Cap0.00
Net Debt to EBITDA1.85
Interest Coverage Ratio-3.09
Taxes
In the past 12 months, Valion Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Valion Bio EV to EBITDA ratio is -32.82, with an EV/FCF ratio of -38.87.
EV to Sales187.09
EV to EBITDA-32.82
EV to Free Cash Flow-38.87
EV to Operating Cash Flow-38.87
Balance Sheet
Valion Bio has $285.39K in cash and marketable securities with $300.00K in debt, giving a net cash position of -$14.61K billion.
Cash & Marketable Securities$285.39K
Total Debt$300.00K
Net Cash-$14.61K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$379.94
Margins
Gross margin is 63.34%, with operating margin of -483.02%, and net profit margin of -728.47%.
Gross Margin63.34%
Operating Margin-483.02%
Pretax Margin-728.39%
Net Profit Margin-728.47%
EBITDA Margin-570.07%
EBIT Margin-572.13%
Analyst Forecast
The average price target for Valion Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-49.63%
EPS Growth Forecast82.22%